Related Experiment Video
Updated: Aug 21, 2025
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
1,3-Dibenzyl-5-Fluorouracil Prevents Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Differentiation
Hyoeun Jeon1, Jungeun Yu1, Jung Me Hwang2
1Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 34134, Korea.
Abstract:
Osteoclasts (OCs) are clinically important cells that resorb bone matrix. Accelerated bone destruction by OCs is closely linked to the development of metabolic bone diseases. In this study, we screened novel chemical inhibitors targeting OC differentiation to identify drug candidates for metabolic bone diseases. We identified that 1,3-dibenzyl-5-fluorouracil, also named OCI-101, is a novel inhibitor of osteoclastogenesis. The formation of multinucleated OCs is reduced by treatment with OCI-101 in a dose-dependent manner. OCI-101 inhibited the expression of OC markers via downregulation of receptor activator of NF-κB ligand and M-CSF signaling pathways. Finally, we showed that OCI-101 prevents ovariectomy-induced bone loss by suppressing OC differentiation in mice. Hence, these results demonstrated that OCI-101 is a good drug candidate for treating metabolic bone diseases.
Insights
A novel compound, OCI-101, effectively inhibits osteoclast differentiation, a key process in metabolic bone diseases. This discovery offers a promising new therapeutic strategy for bone loss conditions.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Osteoclasts (OCs) are critical for bone resorption, and their accelerated activity contributes to metabolic bone diseases.
- Targeting OC differentiation is a key strategy for developing treatments for bone loss.
Purpose of the Study:
- To identify novel chemical inhibitors of osteoclastogenesis for potential metabolic bone disease therapies.
- To evaluate the efficacy of a newly identified inhibitor, OCI-101, in preclinical models.
Main Methods:
- Screening of chemical compounds for inhibition of osteoclast differentiation.
- In vitro assessment of OCI-101's effect on multinucleated OC formation and OC marker expression.
- In vivo evaluation of OCI-101 in an ovariectomy-induced bone loss mouse model.
Main Results:
- 1,3-dibenzyl-5-fluorouracil (OCI-101) was identified as a novel inhibitor of osteoclastogenesis.
- OCI-101 dose-dependently reduced multinucleated OC formation and inhibited key OC markers.
- OCI-101 suppressed ovariectomy-induced bone loss in mice by inhibiting OC differentiation.
Conclusions:
- OCI-101 demonstrates significant potential as a therapeutic agent for metabolic bone diseases.
- The compound acts by downregulating receptor activator of NF-κB ligand and M-CSF signaling pathways.
- OCI-101 represents a promising drug candidate for preventing and treating bone loss.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:40Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...